<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> infantile neurological cutaneous and articular (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CINCA</z:e>) syndrome is a severe auto-<z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disease</z:e>, due to mutation of the CIAS1 gene </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0409818" disease_type="Disease or Syndrome" abbrv="CINCA">CINCA syndrome</z:e> should be considered the most severe of a spectrum of three disorders <z:hpo ids='HP_0000001'>all</z:hpo> due to mutation of the CIAS1 gene </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0409818" disease_type="Disease or Syndrome" abbrv="CINCA">CINCA syndrome</z:e> produces a triad of symptoms of <z:hpo ids='HP_0003623'>neonatal onset</z:hpo>: maculopapular <z:e sem="disease" ids="C0042109" disease_type="Disease or Syndrome" abbrv="">urticarial rash</z:e>, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001287'>meningitis</z:hpo>, and <z:hpo ids='HP_0011010'>chronic</z:hpo> non-inflammatory <z:hpo ids='HP_0003040'>arthropathy</z:hpo> with recurrent <z:hpo ids='HP_0001945'>fever</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0409818" disease_type="Disease or Syndrome" abbrv="CINCA">CINCA syndrome</z:e> is also associated with sensory organ damage, especially <z:hpo ids='HP_0001730'>progressive hearing loss</z:hpo> and <z:hpo ids='HP_0000572'>loss of vision</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>In this case report, we present the first case of cochlear implantation in a 13-year-old child with <z:e sem="disease" ids="C0409818" disease_type="Disease or Syndrome" abbrv="CINCA">CINCA syndrome</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Cochlear implantation was successful at rehabilitating the hearing loss with the child able to continue mainstream education, with her academic performance and speech discrimination both showing marked improvement </plain></SENT>
<SENT sid="6" pm="."><plain>Anakinra (an interleukin 1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>) is now in widespread use to treat <z:e sem="disease" ids="C0409818" disease_type="Disease or Syndrome" abbrv="CINCA">CINCA syndrome</z:e> and is known to rapidly reverse the inflammatory features of <z:e sem="disease" ids="C0409818" disease_type="Disease or Syndrome" abbrv="CINCA">CINCA syndrome</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>However, current evidence suggests that anakinra has limited effectiveness in reversing the <z:mp ids='MP_0004740'>sensorineural hearing loss</z:mp> seen in <z:e sem="disease" ids="C0409818" disease_type="Disease or Syndrome" abbrv="CINCA">CINCA syndrome</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>We therefore propose that cochlear implantation is a viable treatment option in this rare yet severe auto-<z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disease</z:e>, if the patient has failed to respond to anakinra </plain></SENT>
<SENT sid="9" pm="."><plain>Owing to the unknown pathogenesis of the <z:hpo ids='HP_0001730'>progressive hearing loss</z:hpo> seen in <z:e sem="disease" ids="C0409818" disease_type="Disease or Syndrome" abbrv="CINCA">CINCA syndrome</z:e> and the limited effectiveness of anakinra in reversing the <z:hpo ids='HP_0001730'>progressive hearing loss</z:hpo>, we suggest that cochlear implantation is the modality of choice in rehabilitating severe-to-profound hearing loss not responsive to anakinra </plain></SENT>
</text></document>